Adjunctive Brain Volume Quantification Tool for MRI Gets FDA Clearance
Providing automated brain volume calculations based on MRI images, NeuroShield’s artificial intelligence (AI)-powered technology may help facilitate treatment for neurodegenerative conditions ranging from Alzheimer’s disease to epilepsy.
A brain volume quantification tool that may provide early insights on neurodegenerative conditions based on magnetic resonance imaging (MRI) assessment, the artificial intelligence (AI)-enabled NeuroShield has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Currently being utilized in over 200 facilities across the world, NeuroShield offers automated brain volume assessment based upon 3D MRI scans, according to InMed.AI (InMed Prognostics), the developer of NeuroShield.
The company noted that the brain segmentation analysis provided with NeuroShield has demonstrated high accuracy rates across different clinical subgroups and magnetic strengths in a trial of 280 subjects. InMed.AI noted that NeuroShield may aid in the early detection of brain atrophy, possibly facilitating timely intervention for those at risk of dementia, Alzheimer’s disease and other neurodegenerative conditions.
“We believe that investing in our collective human future and that technology is a great lever to move towards precision health to extend quality of life,” added Latha Poonamallee, Ph.D., the founder and CEO of InMed Prognostics.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
